While published data from the Safety and Appropriateness of Growth hormone treatments in Europe (SAGhE) project indicate that GH treatment is not associated with an increased risk of cancer incidence or mortality, risk of circulatory and cerebrovascular disease development appears to be raised in short children born SGA treated with GH (19–21). The gene discussed is GH1; the disease is cerebrovascular disorder.